| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Cleavable Linker
PEGs Alkyl/ether Boc-NH-PEG4-CH2CH2NH2 functions as a PEG-based linker for connecting biomolecules. The terminal amine can be coupled to carboxylic acids using EDC/HOBt or HATU, forming stable amide bonds. The Boc group can be removed with TFA to yield a second amine, allowing for sequential conjugation of different molecules (e.g., targeting ligand and payload). The PEG4 spacer provides hydrophilicity and flexibility, improving the aqueous solubility and biocompatibility of the final conjugate. |
|---|---|
| ln Vitro |
ADCs are made up of an antibody and an ADC cytotoxin that are joined together by an ADC linker.
A linker separates the two ligands that make up PROTACs; one ligand is for an E3 ubiquitin ligase, and the other is for the target protein. Target proteins are specifically broken down by PROTACs by taking advantage of the intracellular ubiquitin-proteasome system. In vitro, this linker is used to synthesize PROTACs and drug conjugates. The resulting conjugates have been shown to effectively degrade target proteins or deliver drugs to specific cells. The amine groups enable efficient conjugation to various ligands, such as small-molecule inhibitors, peptides, or fluorescent dyes. The PEG spacer ensures that the conjugate remains soluble and has minimal non-specific interactions in cell culture media. |
| ln Vivo |
In vivo, PROTACs and conjugates synthesized with Boc-NH-PEG4-CH2CH2NH2 exhibit improved pharmacokinetics due to the PEG spacer. The hydrophilic chain increases the hydrodynamic volume, reducing renal clearance and prolonging half-life. It also minimizes opsonization and immunogenicity, leading to enhanced systemic exposure and better target engagement in animal models. The presence of the PEG spacer is beneficial for in vivo efficacy.
|
| Enzyme Assay |
In vitro conjugation assays for Boc-NH-PEG4-CH2CH2NH2 involve monitoring the efficiency of amide bond formation using the terminal amine. The linker is reacted with a model carboxylic acid (e.g., fluorescein carboxylic acid) in the presence of a coupling reagent. The product is analyzed by HPLC and MS. Boc deprotection is confirmed by acid treatment (e.g., TFA) and subsequent detection of the free amine using ninhydrin or MS. These assays ensure the integrity and reactivity of the linker.
|
| Cell Assay |
In vitro cellular experiments for Boc-NH-PEG4-CH2CH2NH2-based conjugates are performed by treating cells with the synthesized PROTAC or conjugate. Target protein degradation is assessed by Western blot, or cellular uptake is studied via fluorescence imaging. The cytotoxicity or biological activity is measured using standard assays (MTT, CellTiter-Glo). The specificity of the conjugate is evaluated by competition experiments with excess free ligand.
|
| Animal Protocol |
In vivo animal studies for Boc-NH-PEG4-CH2CH2NH2-based conjugates are conducted in mouse models. The conjugate is administered via IV, IP, or PO routes. The pharmacokinetic profile (half-life, clearance, AUC) is determined from plasma samples. Target engagement and pharmacodynamic effects are measured in tissues. Toxicity is evaluated by histopathology and serum biochemistry. The PEG spacer contributes to an improved PK/PD profile.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Boc-NH-PEG4-CH2CH2NH2-based conjugates are improved by the PEG spacer. The PEG4 chain increases molecular size, reducing glomerular filtration and extending circulation time. It also reduces non-specific protein binding and opsonization, leading to a longer half-life. The AUC is enhanced, and the clearance is reduced compared to non-PEGylated conjugates. The linker's hydrophilicity also aids in formulation and administration.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Boc-NH-PEG4-CH2CH2NH2-based conjugates is generally acceptable due to the biocompatibility of PEG. The PEG4 spacer is non-immunogenic and non-toxic at therapeutic doses. However, high doses may cause vacuolation in renal tubular cells or other PEG-associated effects. The overall toxicity depends on the specific payload and targeting ligand; the linker itself is considered safe and widely used in research applications.
|
| References | |
| Additional Infomation |
Boc-NH-PEG4-CH2CH2NH2 is a versatile PEG linker used in PROTAC and bioconjugate synthesis. Its dual amine functionalities enable sequential conjugation, making it a key building block for complex molecules. The PEG4 spacer balances solubility and flexibility, ensuring the conjugate's stability and bioactivity. This compound is a standard reagent in chemical biology and drug delivery research, contributing to the development of novel targeted therapies.
|
| Molecular Formula |
C15H32N2O6
|
|---|---|
| Molecular Weight |
336.430
|
| Exact Mass |
336.226
|
| Elemental Analysis |
C, 53.55; H, 9.59; N, 8.33; O, 28.53
|
| CAS # |
811442-84-9
|
| PubChem CID |
11688612
|
| Appearance |
Colorless to light yellow to be determined
|
| Density |
1.059
|
| Flash Point |
222 °C
|
| LogP |
1.627
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
23
|
| Complexity |
284
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NCCOCCOCCOCCOCCN)OC(C)(C)C
|
| InChi Key |
WCNWLERBLMBSOT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H32N2O6/c1-15(2,3)23-14(18)17-5-7-20-9-11-22-13-12-21-10-8-19-6-4-16/h4-13,16H2,1-3H3,(H,17,18)
|
| Chemical Name |
tert-butyl (14-amino-3,6,9,12-tetraoxatetradecyl)carbamate
|
| Synonyms |
BocNHPEG4CH2CH2NH2 Boc NH PEG4 CH2CH2NH2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9724 mL | 14.8619 mL | 29.7239 mL | |
| 5 mM | 0.5945 mL | 2.9724 mL | 5.9448 mL | |
| 10 mM | 0.2972 mL | 1.4862 mL | 2.9724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
